\n\n\n\n\t\t\n\t\t\tVital Therapies\n\t\t\thttp://www.vitaltherapies.com/\n\t\t
\n\t\t\n\t\t\tWatch Company\n\t\t\tGet Widget\n\t\t
\n\tVital Therapies, Inc. (VTI) is a new company formed in 2003 to continue the development of the ELAD\xae (Extracorporeal Liver Assist Device) System, which augments the metabolic functions of a patient\u2019s...More»
\n\t\t\tVital Therapies, Inc. (VTI) is a new company formed in 2003 to continue the development of the ELAD\xae (Extracorporeal Liver Assist Device) System, which augments the metabolic functions of a patient\u2019s liver, thereby enabling a bridge to transplant or liver recovery. VTI acquired the assets and business of VitaGen/Hepatix.
The sole therapy for serious liver disease is transplantation. In 2002, over 5,000 liver transplants were performed in the United States, restricted by available donor organs: another 17,000 patients are on the transplant waiting list. Many of the patients on the list die while waiting for a transplant.
In a market study done for VTI by Easton Associates in October 2003, they concluded that there were 21,290 patients eligible for ELAD\xae therapy in the US in 2003 and that the theoretical market potential in the US is $1.08 Billion/year.«Less
Overview
\n\t\t\t\tLocation: \tSan Diego, CA, United States\n
\n\t\t\t\tIndustry: Medical Devices & Equipment
\n\t\t\t\tEmployees: 35
\n\t\t\t\tTags:\n\t\t\t\tclinical trials,\n\t\t\t\tTechnology,\n\t\t\t\tliver,\n\t\t\t\tdisease,\n\t\t\t\trecovery,\n\t\t\t\ttransplant,\n\t\t\t\tmetabolic\n\t\t\t\t
\n\t\t\tMarket
\n\t\t\t\tCompetitors:\n\t\t\t\t\t\tMedigen Biotechnology\n\t\t\t\t
\n\n\t\t\t\tRelated Companies:\n\t\t\t\t\tThreshold Pharmaceuticals,\n\t\t\t\t\tOcera Therapeutics,\n\t\t\t\t\tInMage,\n\t\t\t\t\tEsperion Therapeutics,\n\t\t\t\t\tDelphic Europe,\n\t\t\t\t\tUromedica\n\t\t\t\t
\n\t\t\t